Drug Trial Radar · NCT06277934
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Mar 8, 2024
Primary completion
Aug 13, 2024
Study completion Aug 13, 2024
Sponsor
- Lead sponsor
- Regor Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
Conditions
- Obesity
Interventions
RGT001-075Drug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment-emergent Adverse Event(AE) by severity/Serious Adverse Event (SAE), with Clinical Laboratory Abnormalities, Clinically Significant Change From Baseline in Vital Signs and Abnormal Electrocardiogram(ECG) readingsTime frame: 14 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Velocity Clinical Research
Los Angeles, California
Velocity Clinical Research
Valparaiso, Indiana
Velocity Clinical Research
Omaha, Nebraska
Velocity Clinical Research
Vestal, New York
Velocity Clinical Research
Durham, North Carolina
Velocity Clinical Research
Cleveland, Ohio
Velocity Clinical Research
Medford, Oregon
Velocity Clinical Research
East Greenwich, Rhode Island
Velocity Clinical Research
Dallas, Texas
Velocity Clinical Research
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.